Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322626707> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4322626707 endingPage "1072" @default.
- W4322626707 startingPage "1065" @default.
- W4322626707 abstract "Background/Aim: Cytotoxic inhalable drugs were shown to be advantageous in treating malignancies of the respiratory tract. However, these drugs have not always presented a safe profile and were reported to induce local adverse events. Protein-based anticancer drugs, such as immune checkpoint and vascular endothelial growth factor inhibitors, do not induce tissue injury, nor do they exhibit vesicant properties upon direct contact with tissues. Protein drugs are susceptible to the heat and stress encountered during droplet generation for delivery by nebulization. The aim of this study was to investigate the capacity of atezolizumab, an antibody to programmed death ligand 1, to bind target cells after nebulization with a vibrating mesh (VM) nebulizer. Materials and Methods: We compared Fourier-transformed infrared (FTIR) and Raman spectra of native atezolizumab (60 mg/ml) and its nebulized form following 10-min nebulization in a piezoceramic VM nebulizer. The binding of atezolizumab to DU-145 prostate cancer cells was evaluated using competitive blocking of anti-CD274 staining. Results: Nebulization did not induce Raman or FTIR spectral modification nor did it affect the binding capacity of atezolizumab. Conversely, heat-inactivated atezolizumab lost its cell-binding capacity and did not reduce anti-CD274 immunostaining. Native and nebulized atezolizumab displayed identical spectra, whereas the FTIR spectra of the heat-inactivated drug was significantly altered. Conclusion: VM nebulization does not obliterate the functionality of the drug atezolizumab. The integrity of a nebulized form can be rapidly assessed by FTIR and Raman spectrometry." @default.
- W4322626707 created "2023-03-01" @default.
- W4322626707 creator A5000144406 @default.
- W4322626707 creator A5000863324 @default.
- W4322626707 creator A5003018009 @default.
- W4322626707 creator A5029462266 @default.
- W4322626707 creator A5037059229 @default.
- W4322626707 creator A5043538484 @default.
- W4322626707 creator A5050666681 @default.
- W4322626707 creator A5068469027 @default.
- W4322626707 creator A5072012380 @default.
- W4322626707 creator A5078720382 @default.
- W4322626707 creator A5084963604 @default.
- W4322626707 date "2023-02-28" @default.
- W4322626707 modified "2023-10-01" @default.
- W4322626707 title "Atezolizumab Retains Cellular Binding to Programmed Death Ligand 1 Following Aerosolization<i>via</i>Mesh Nebulizer" @default.
- W4322626707 doi "https://doi.org/10.21873/anticanres.16251" @default.
- W4322626707 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36854531" @default.
- W4322626707 hasPublicationYear "2023" @default.
- W4322626707 type Work @default.
- W4322626707 citedByCount "0" @default.
- W4322626707 crossrefType "journal-article" @default.
- W4322626707 hasAuthorship W4322626707A5000144406 @default.
- W4322626707 hasAuthorship W4322626707A5000863324 @default.
- W4322626707 hasAuthorship W4322626707A5003018009 @default.
- W4322626707 hasAuthorship W4322626707A5029462266 @default.
- W4322626707 hasAuthorship W4322626707A5037059229 @default.
- W4322626707 hasAuthorship W4322626707A5043538484 @default.
- W4322626707 hasAuthorship W4322626707A5050666681 @default.
- W4322626707 hasAuthorship W4322626707A5068469027 @default.
- W4322626707 hasAuthorship W4322626707A5072012380 @default.
- W4322626707 hasAuthorship W4322626707A5078720382 @default.
- W4322626707 hasAuthorship W4322626707A5084963604 @default.
- W4322626707 hasBestOaLocation W43226267071 @default.
- W4322626707 hasConcept C185592680 @default.
- W4322626707 hasConcept C203014093 @default.
- W4322626707 hasConcept C2775949291 @default.
- W4322626707 hasConcept C2776954882 @default.
- W4322626707 hasConcept C2777701055 @default.
- W4322626707 hasConcept C2780057760 @default.
- W4322626707 hasConcept C2780352487 @default.
- W4322626707 hasConcept C42219234 @default.
- W4322626707 hasConcept C71924100 @default.
- W4322626707 hasConcept C82085835 @default.
- W4322626707 hasConcept C8891405 @default.
- W4322626707 hasConcept C98274493 @default.
- W4322626707 hasConceptScore W4322626707C185592680 @default.
- W4322626707 hasConceptScore W4322626707C203014093 @default.
- W4322626707 hasConceptScore W4322626707C2775949291 @default.
- W4322626707 hasConceptScore W4322626707C2776954882 @default.
- W4322626707 hasConceptScore W4322626707C2777701055 @default.
- W4322626707 hasConceptScore W4322626707C2780057760 @default.
- W4322626707 hasConceptScore W4322626707C2780352487 @default.
- W4322626707 hasConceptScore W4322626707C42219234 @default.
- W4322626707 hasConceptScore W4322626707C71924100 @default.
- W4322626707 hasConceptScore W4322626707C82085835 @default.
- W4322626707 hasConceptScore W4322626707C8891405 @default.
- W4322626707 hasConceptScore W4322626707C98274493 @default.
- W4322626707 hasIssue "3" @default.
- W4322626707 hasLocation W43226267071 @default.
- W4322626707 hasLocation W43226267072 @default.
- W4322626707 hasOpenAccess W4322626707 @default.
- W4322626707 hasPrimaryLocation W43226267071 @default.
- W4322626707 hasRelatedWork W2010086681 @default.
- W4322626707 hasRelatedWork W2037110469 @default.
- W4322626707 hasRelatedWork W2078871334 @default.
- W4322626707 hasRelatedWork W2121677473 @default.
- W4322626707 hasRelatedWork W2123528023 @default.
- W4322626707 hasRelatedWork W2153570759 @default.
- W4322626707 hasRelatedWork W2315984411 @default.
- W4322626707 hasRelatedWork W4210383442 @default.
- W4322626707 hasRelatedWork W4283170448 @default.
- W4322626707 hasRelatedWork W4306766609 @default.
- W4322626707 hasVolume "43" @default.
- W4322626707 isParatext "false" @default.
- W4322626707 isRetracted "false" @default.
- W4322626707 workType "article" @default.